康方生物(09926.HK)就PD-1单抗派安普利(安尼可)联合抗肿瘤血管生成药物安罗替尼一线治疗晚期肝细胞癌临试资料摘要获ASCO年会以海报形式呈列
格隆汇5月19日丨康方生物－Ｂ(09926.HK)发布公告，关于由公司与中国生物制药(01177.HK)共同开发及商业化的派安普利单抗(AK105，PD-1 单抗)联合安罗替尼一线治疗晚期肝细胞癌的临床疗效和安全性二期研究资料摘要已获即将召开的2020年美国临床肿瘤学会(“ASCO”)年会接受以海报形式呈列。具体细节将于2020年5月29日后在公司网站上发布。
公告表示，派安普利单抗(AK105，PD-1单抗)由公司与中国生物制药旗下正大天晴所设立的合营企业共同开发及商业化。派安普利是中国生物制药唯一可用于开发基于 PD-1抗体的单一疗法或联合疗法的新药，亦是公司处于临床开发后期、具差异化且可能是同类最佳的PD-1创新性单克隆抗体候选药物。派安普利的Fc受体和补体介导效用功能通过Fc区突变而完全去除，同时与国外已上市PD-1抗体相比抗原结合解离速率较慢。这些特点使得派安普利具有更有效地阻断PD-1通路的活性，并维持更强的T细胞抗肿瘤活性，有可能成为临床获益更好的抗PD-1药物。
此外，安罗替尼(福可维®)是正大天晴自主研发的一类口服、新型小分子多靶点酪氨酸激酶抑制剂，具有抗肿瘤血管生成和抑制肿瘤生长的作用。现有研究证据表明，安罗替尼对多个癌种均有效，是全球首个同时拥有非小细胞肺癌、小细胞肺癌、软组织肉瘤三大适应证的抗血管生成药物，填补了多项恶性肿瘤治疗空白。2015 年和2017年安罗替尼先后获FDA卵巢癌和软组织肉瘤孤儿药认证。2018年上市后，安罗替尼获得多个专业协会╱学会的权威指南推荐，且被中国医药创新促进会评为2018年度唯一的“最具临床价值创新药”。安罗替尼已在《JAMA Oncology》等SCI期刊发表论文40余篇，累计影响因子超180；40多项研究成果在ASCO/ WCLC/ESMO等国际权威学术会议上公布，引起全球广泛关注。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
